dengue vaccine Qdenga
Selected indexed studies
- Qdenga® - A promising dengue fever vaccine; can it be recommended to non-immune travelers? (Travel Med Infect Dis, 2023) [PMID:37271201]
- Qdenga-induced dengue caused by minor DENV-2 subvariant(s) in the vaccine, with two amino acid substitutions in the E protein. (J Travel Med, 2025) [PMID:40913469]
- Dengue Vaccines. (Curr Top Microbiol Immunol, 2026) [PMID:40794141]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Qdenga® - A promising dengue fever vaccine; can it be recommended to non-immune travelers? (2023) pubmed
- Qdenga-induced dengue caused by minor DENV-2 subvariant(s) in the vaccine, with two amino acid substitutions in the E protein. (2025) pubmed
- Dengue Vaccines. (2026) pubmed
- First clinical experiences with the tetravalent live vaccine against dengue (Qdenga®) in travellers: a multicentric TravVacNet study in Germany. (2025) pubmed
- Dengue Vaccine Development and Deployment into Routine Immunization. (2025) pubmed
- Efficacy, public health impact and optimal use of the Takeda dengue vaccine. (2025) pubmed
- Vaccination against dengue fever for travellers. (2024) pubmed
- The Tolerability of the Dengue Vaccine TAK-003 (Qdenga(®)) in German Travelers: The Results of a Prospective Survey. (2025) pubmed
- The current dengue vaccine landscape, with a focus on TAK-003 (Qdenga®). (2026) pubmed
- Development of New Live-Attenuated Vaccine Candidates Lacking Antibody-Dependent Enhancement (ADE) Against Dengue. (2025) pubmed